Fortrea Holdings Inc. (FTRE)
- Previous Close
35.50 - Open
35.71 - Bid 35.69 x 800
- Ask 35.83 x 300
- Day's Range
35.03 - 36.11 - 52 Week Range
24.92 - 41.02 - Volume
707,510 - Avg. Volume
858,949 - Market Cap (intraday)
3.2B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.04 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.50
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
www.fortrea.comRecent News: FTRE
Performance Overview: FTRE
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FTRE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FTRE
Valuation Measures
Market Cap
3.17B
Enterprise Value
4.74B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.01
Price/Book (mrq)
1.82
Enterprise Value/Revenue
1.53
Enterprise Value/EBITDA
28.35
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.11%
Return on Assets (ttm)
1.26%
Return on Equity (ttm)
-0.13%
Revenue (ttm)
3.11B
Net Income Avi to Common (ttm)
-3.4M
Diluted EPS (ttm)
-0.04
Balance Sheet and Cash Flow
Total Cash (mrq)
108.6M
Total Debt/Equity (mrq)
96.65%
Levered Free Cash Flow (ttm)
154.8M
Research Analysis: FTRE
Company Insights: FTRE
FTRE does not have Company Insights